Quarantine Advice Update


Further to DrugAlert Volume 232, HPS Pharmacies wish to advise that AFT Pharmaceuticals have provided an update regarding the temporary quarantine of:

Provive® Injection Vials, 5 x 20mL
(propofol 10mg/mL)
Aust R 118938
Batches A040656 and A040666

Despite an increase in the number and severity of reports of shivering and rigors, these adverse reactions were found to be consistent with the expected frequency of 2% of patients administered propofol of any brand, as described in the product information.

Investigation has shown that these batches meet all specifications, including microbial and chemical quality as tested by the Therapeutic Goods Administration.

Any stock that remains in quarantine may now be returned to use. However, if staff have concerns regarding the safety of the above named batches, AFT Pharmaceuticals have offered to exchange any remaining vials with an alternative batch.

Retain this notice in a prominent position, including in other related business units for one month in case stock is in transit. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies. Alternatively, please contact AFT Pharmaceuticals on 1800 238 74276 or via email at customer.service@aftpharm.com.

Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates